• Claire Philippe, Fabien Wauquier, Bernard Lyan, Véronique Coxam, and Yohann Wittrant.
• INRA, UMR 1019, UNH, CRNH Auvergne, 63009, Clermont-Ferrand, France.
• Mol. Cell. Biochem. 2016 Jan 1; 412 (1-2): 197-208.

AbstractGPR40 is a free fatty acid receptor that has been recently shown to impact bone remodeling. This receptor protects skeleton by inhibiting bone resorbing osteoclast differentiation. Consistent with GPR40 expression on bone forming cells, we assumed that this receptor may also influence osteoblast activity. To further investigate this hypothesis, biological effects of GW9508, a synthetic agonist for GPR40, was first tested on osteoblast differentiation parameters. Assays were performed in two different cell models: the MC3T3-E1 osteoblastic cell line and primary bone marrow cultures extracted from wild-type and GPR40 knock-out mice. Both models showed a dual role of GPR40 on osteoblasts. Although receptor stimulation induced early stimulation of differentiation marker expression, it finally led to inhibition of mineralization process during late differentiation stages. To further elucidate this discrepancy, mice were ovariectomized to induce bone loss and received GPR40 agonist by gavage. Data revealed a weak influence of GPR40 agonist on osteoblast markers expression. Nevertheless, a significant increase in OPG expression was observed upon GW9508 treatment that contribute to explain the GPR40-related osteoporosis prevention. To conclude, our results confirm the relevance of this new opportunity in the management of bone loss.

25 keywords...

hide…